Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.11
BAYRY's Cash to Debt is ranked lower than
92% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. BAYRY: 0.11 )
Ranked among companies with meaningful Cash to Debt only.
BAYRY' s 10-Year Cash to Debt Range
Min: 0.08  Med: 0.31 Max: No Debt
Current: 0.11
Equity to Asset 0.28
BAYRY's Equity to Asset is ranked lower than
89% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BAYRY: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
BAYRY' s 10-Year Equity to Asset Range
Min: 0.21  Med: 0.35 Max: 0.46
Current: 0.28
0.21
0.46
F-Score: 6
Z-Score: 2.03
M-Score: -2.45
WACC vs ROIC
8.90%
9.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 9.84
BAYRY's Operating margin (%) is ranked higher than
56% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. BAYRY: 9.84 )
Ranked among companies with meaningful Operating margin (%) only.
BAYRY' s 10-Year Operating margin (%) Range
Min: -4.21  Med: 9.64 Max: 12.29
Current: 9.84
-4.21
12.29
Net-margin (%) 7.55
BAYRY's Net-margin (%) is ranked higher than
56% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.85 vs. BAYRY: 7.55 )
Ranked among companies with meaningful Net-margin (%) only.
BAYRY' s 10-Year Net-margin (%) Range
Min: -4.41  Med: 5.85 Max: 14.56
Current: 7.55
-4.41
14.56
ROE (%) 16.13
BAYRY's ROE (%) is ranked higher than
76% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.87 vs. BAYRY: 16.13 )
Ranked among companies with meaningful ROE (%) only.
BAYRY' s 10-Year ROE (%) Range
Min: -9.14  Med: 12.22 Max: 31.97
Current: 16.13
-9.14
31.97
ROA (%) 5.18
BAYRY's ROA (%) is ranked higher than
59% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. BAYRY: 5.18 )
Ranked among companies with meaningful ROA (%) only.
BAYRY' s 10-Year ROA (%) Range
Min: -3.18  Med: 3.98 Max: 8.79
Current: 5.18
-3.18
8.79
ROC (Joel Greenblatt) (%) 23.54
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.80 vs. BAYRY: 23.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BAYRY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.18  Med: 19.33 Max: 34.99
Current: 23.54
7.18
34.99
Revenue Growth (3Y)(%) 5.00
BAYRY's Revenue Growth (3Y)(%) is ranked lower than
53% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. BAYRY: 5.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BAYRY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.6  Med: 2.25 Max: 14
Current: 5
-10.6
14
EPS Growth (3Y)(%) 11.50
BAYRY's EPS Growth (3Y)(%) is ranked higher than
61% of the 447 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. BAYRY: 11.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BAYRY' s 10-Year EPS Growth (3Y)(%) Range
Min: -19.1  Med: 7.35 Max: 41.4
Current: 11.5
-19.1
41.4
» BAYRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BAYRY Guru Trades in Q2 2014

Ken Fisher 2,302,369 sh (+750.48%)
» More
Q3 2014

BAYRY Guru Trades in Q3 2014

Ken Fisher 2,511,364 sh (+9.08%)
» More
Q4 2014

BAYRY Guru Trades in Q4 2014

Ken Fisher 2,493,419 sh (-0.71%)
» More
Q1 2015

BAYRY Guru Trades in Q1 2015

Ken Fisher 2,509,075 sh (+0.63%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 31.47
BAYRY's P/E(ttm) is ranked higher than
53% of the 469 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.80 vs. BAYRY: 31.47 )
Ranked among companies with meaningful P/E(ttm) only.
BAYRY' s 10-Year P/E(ttm) Range
Min: 8.67  Med: 22.66 Max: 36.88
Current: 31.47
8.67
36.88
Forward P/E 16.50
BAYRY's Forward P/E is ranked higher than
66% of the 244 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.58 vs. BAYRY: 16.50 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.20
BAYRY's PE(NRI) is ranked higher than
52% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.50 vs. BAYRY: 33.20 )
Ranked among companies with meaningful PE(NRI) only.
BAYRY' s 10-Year PE(NRI) Range
Min: 14.08  Med: 23.70 Max: 37.24
Current: 33.2
14.08
37.24
P/B 4.81
BAYRY's P/B is ranked lower than
63% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. BAYRY: 4.81 )
Ranked among companies with meaningful P/B only.
BAYRY' s 10-Year P/B Range
Min: 1.22  Med: 2.41 Max: 5.56
Current: 4.81
1.22
5.56
P/S 2.39
BAYRY's P/S is ranked higher than
62% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. BAYRY: 2.39 )
Ranked among companies with meaningful P/S only.
BAYRY' s 10-Year P/S Range
Min: 0.48  Med: 1.27 Max: 2.76
Current: 2.39
0.48
2.76
PFCF 25.95
BAYRY's PFCF is ranked higher than
69% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.65 vs. BAYRY: 25.95 )
Ranked among companies with meaningful PFCF only.
BAYRY' s 10-Year PFCF Range
Min: 7.28  Med: 16.07 Max: 187
Current: 25.95
7.28
187
POCF 16.33
BAYRY's POCF is ranked higher than
71% of the 399 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.21 vs. BAYRY: 16.33 )
Ranked among companies with meaningful POCF only.
BAYRY' s 10-Year POCF Range
Min: 5.05  Med: 8.85 Max: 19.35
Current: 16.33
5.05
19.35
EV-to-EBIT 27.87
BAYRY's EV-to-EBIT is ranked lower than
51% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.91 vs. BAYRY: 27.87 )
Ranked among companies with meaningful EV-to-EBIT only.
BAYRY' s 10-Year EV-to-EBIT Range
Min: -17.9  Med: 17.00 Max: 31.4
Current: 27.87
-17.9
31.4
PEG 10.06
BAYRY's PEG is ranked lower than
78% of the 245 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. BAYRY: 10.06 )
Ranked among companies with meaningful PEG only.
BAYRY' s 10-Year PEG Range
Min: 0.6  Med: 3.09 Max: 8.76
Current: 10.06
0.6
8.76
Shiller P/E 40.32
BAYRY's Shiller P/E is ranked lower than
53% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.23 vs. BAYRY: 40.32 )
Ranked among companies with meaningful Shiller P/E only.
BAYRY' s 10-Year Shiller P/E Range
Min: 13.45  Med: 27.20 Max: 50.98
Current: 40.32
13.45
50.98
Current Ratio 1.23
BAYRY's Current Ratio is ranked lower than
82% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. BAYRY: 1.23 )
Ranked among companies with meaningful Current Ratio only.
BAYRY' s 10-Year Current Ratio Range
Min: 1  Med: 1.55 Max: 2.13
Current: 1.23
1
2.13
Quick Ratio 0.80
BAYRY's Quick Ratio is ranked lower than
85% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. BAYRY: 0.80 )
Ranked among companies with meaningful Quick Ratio only.
BAYRY' s 10-Year Quick Ratio Range
Min: 0.64  Med: 1.02 Max: 1.44
Current: 0.8
0.64
1.44
Days Inventory 138.90
BAYRY's Days Inventory is ranked lower than
63% of the 616 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.37 vs. BAYRY: 138.90 )
Ranked among companies with meaningful Days Inventory only.
BAYRY' s 10-Year Days Inventory Range
Min: 126.63  Med: 136.05 Max: 174.79
Current: 138.9
126.63
174.79
Days Sales Outstanding 95.55
BAYRY's Days Sales Outstanding is ranked lower than
66% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.51 vs. BAYRY: 95.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAYRY' s 10-Year Days Sales Outstanding Range
Min: 64.79  Med: 70.56 Max: 79.65
Current: 95.55
64.79
79.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.74
BAYRY's Dividend Yield is ranked higher than
62% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. BAYRY: 1.74 )
Ranked among companies with meaningful Dividend Yield only.
BAYRY' s 10-Year Dividend Yield Range
Min: 1.44  Med: 2.35 Max: 3.93
Current: 1.74
1.44
3.93
Dividend Payout 0.52
BAYRY's Dividend Payout is ranked lower than
71% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. BAYRY: 0.52 )
Ranked among companies with meaningful Dividend Payout only.
BAYRY' s 10-Year Dividend Payout Range
Min: 0.98  Med: 1.84 Max: 2.85
Current: 0.52
0.98
2.85
Dividend growth (3y) 11.90
BAYRY's Dividend growth (3y) is ranked higher than
60% of the 246 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. BAYRY: 11.90 )
Ranked among companies with meaningful Dividend growth (3y) only.
BAYRY' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 1.80 Max: 34.9
Current: 11.9
0
34.9
Yield on cost (5-Year) 2.69
BAYRY's Yield on cost (5-Year) is ranked higher than
74% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.34 vs. BAYRY: 2.69 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAYRY' s 10-Year Yield on cost (5-Year) Range
Min: 2.23  Med: 3.63 Max: 6.07
Current: 2.69
2.23
6.07

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.85
BAYRY's Price/Projected FCF is ranked higher than
62% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. BAYRY: 1.85 )
Ranked among companies with meaningful Price/Projected FCF only.
BAYRY' s 10-Year Price/Projected FCF Range
Min: 0.71  Med: 1.42 Max: 2.14
Current: 1.85
0.71
2.14
Price/DCF (Earnings Based) 2.22
BAYRY's Price/DCF (Earnings Based) is ranked lower than
67% of the 51 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.65 vs. BAYRY: 2.22 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.69
BAYRY's Price/Median PS Value is ranked lower than
73% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. BAYRY: 1.69 )
Ranked among companies with meaningful Price/Median PS Value only.
BAYRY' s 10-Year Price/Median PS Value Range
Min: 0.25  Med: 0.92 Max: 3.61
Current: 1.69
0.25
3.61
Earnings Yield (Greenblatt) (%) 3.78
BAYRY's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. BAYRY: 3.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAYRY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.2  Med: 5.80 Max: 13.9
Current: 3.78
3.2
13.9
Forward Rate of Return (Yacktman) (%) 7.20
BAYRY's Forward Rate of Return (Yacktman) (%) is ranked higher than
50% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. BAYRY: 7.20 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAYRY' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 2.2  Med: 14.00 Max: 31.6
Current: 7.2
2.2
31.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BAY.Italy, BAY.Spain, BAYN N.Mexico, BAYN.Switzerland, BAYA.Germany, BAYN.Germany,
Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third- largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing extensive customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.
» More Articles for OTCPK:BAYRY

Headlines

Articles On GuruFocus.com
Bayer AG Wins Approval On Existing Antibiotic For Plague Treatment May 12 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
DuPont Eyeing Acquisition To Leverage Its Market Spread Apr 24 2015 
savings Apr 22 2015 
Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 

More From Other Websites
Design students discover new creative possibilities with polycarbonate -- Creative material... Jul 03 2015
Bayer Pearl introduces new polyurethane spray foam system in Middle East -- Excellent thermal... Jul 02 2015
Bayer Files Hemophilia A Drug Marketing Application in Japan - Analyst Blog Jul 01 2015
FDA OKs second test to see if Essure contraceptive is placed right Jul 01 2015
Bayer shares climb on birth-control confirmation test Jul 01 2015
Dr. Jacqueline Applegate to head Environmental Science at Bayer CropScience Jul 01 2015
If Syngenta deal fizzles, here’s what a Monsanto bid for Bayer might look like Jun 30 2015
Regeneron/Bayer's Eylea Gets Label Expansion in Japan - Analyst Blog Jun 29 2015
Conference at Bayer CropScience in Monheim: -- A flood of research data offers opportunities for new... Jun 26 2015
FDA Receives Complaints From Women About Sterilization Implant Jun 24 2015
FDA panel to discuss safety of Bayer's contraceptive device Essure Jun 24 2015
Monsanto Says Bayer Among Options If Syngenta Deal Fails Jun 23 2015
Process innovation from Bayer MaterialScience: -- German state minister honors electricity-saving... Jun 19 2015
Helping to spark interest of girls in science-related subjects: -- Bayer MaterialScience starts new... Jun 18 2015
Bayer CropScience streamlines executive responsibilities Jun 17 2015
13th International Conference on Malignant Lymphoma (ICML): -- Bayer to Present New Data on... Jun 17 2015
Not intended for UK Media -- Bayer HealthCare and Johns Hopkins University Collaborate to Develop... Jun 16 2015
Bayer to Present Latest Advances in Hemophilia Research at the ISTH 2015 Annual Congress in Toronto Jun 15 2015
New Clinical Data Further Supporting the Positive Benefit Risk Profile of Bayer’s Xarelto® and... Jun 15 2015
Bayer (BAYRY) Up on Deal to Sell Diabetes Care Business - Analyst Blog Jun 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK